Meglumine Antimonate, identified by its CAS number 133-51-7, stands as a significant compound in the pharmaceutical landscape, primarily recognized for its efficacy in treating leishmaniasis. This debilitating disease, caused by protozoan parasites of the genus Leishmania, affects millions worldwide, and Meglumine Antimonate has been a frontline therapeutic option for decades. The compound's antiprotozoal properties are directly linked to its antimony content, which disrupts essential metabolic pathways within the parasite, ultimately leading to its demise. NINGBO INNO PHARMCHEM CO.,LTD. is a key contributor in supplying this vital pharmaceutical intermediate.

The administration of Meglumine Antimonate typically involves injection, a method facilitated by its solubility in water. This characteristic ensures that the drug can be effectively delivered to the bloodstream, reaching the sites of parasitic infection. The precise dosage and treatment regimen are contingent upon the specific species of Leishmania causing the infection and the clinical presentation of the disease. While generally effective, like many potent medications, it can have associated side effects, including localized pain at the injection site and potential systemic toxicity, necessitating careful medical supervision during treatment. The availability of reliable sources for this compound, such as from NINGBO INNO PHARMCHEM CO.,LTD., is crucial for patient care.

Beyond its established role, understanding the meglumine antimonate pharmaceutical applications and sourcing opportunities is vital for healthcare providers and the pharmaceutical industry. The demand for high-quality Meglumine Antimonate, often sought through direct purchase from reputable manufacturers like NINGBO INNO PHARMCHEM CO.,LTD., remains consistent. The company's commitment to providing essential pharmaceutical intermediates ensures that this life-saving medication continues to be accessible.